FTD-TPI, Bevacizumab, and Radioembolization With 166Ho-microspheres in Refractory Metastatic Colorectal Cancer

Extrahepatic disease progression limits clinical efficacy of individualized radioembolization for patients with refractory metastatic colorectal cancer (mCRC). In the same patient population, trifluridine/tipiracil (FTD-TPI) and bevacizumab lead to disease control and overall survival benefit and may be a radiosensitizer. The purpose of this study is to determine safety, tolerability, and activity of individualized radioembolization with 166Holmium (166Ho)-microspheres combined with FTD-TPI and bevacizumab.

Trial Details

NCT ID
NCT06563986
Phase
PHASE2
Sponsor
UMC Utrecht
Status
RECRUITING
Cancer Type
Colorectal Cancer
Interventions
  • Systemic treatment (FTD-TPI and bevacizumab)
  • Radioembolization with 166-Ho microspheres
Locations (sample)
  • Utrecht, Netherlands|52.09083,5.12222

Key Eligibility Criteria

  • Unresectable liver dominant mCRC
  • Prior therapy with fluoropyrimidine, oxaliplatin, and irinotecan for the treatment of metastatic colorectal cancer and had demonstrated progressive…
  • Patients who have withdrawn from standard treatment due to unacceptable toxicity warranting discontinuation of treatment and precluding retreatment…
  • Patients who refuse oxaliplatin or irinotecan will also be eligible to enter the study.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colorectal Cancer Trials on Trialify →